Other drugs being currently tested target C1r and C1s (C1-INH for kidney transplantation), C3 (APL-2 for IgAN, LN, MGN, C3G, membranoproliferative glomerulonephritis (MPGN)), C5a (IFX-1 for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis), C5aR1 (Avacopan for C3G and ANCA- associated vasculitis), complement factor D (ACH-4471 for C3G, MPGN and ALXN2050 for renal impairment) and mannan-binding lectin serine protease 2 (OMS721 for IgAN, LN, MGN, C3G). This evidence concerns the gene C5AR1 and complement 3 glomerulopathy.